Interleukin ( 
Transfer of cytokine genes into tumor cells has proven a valuable approach for the analysis of cytokine-mediated effects on tumor growth [interleukin (IL)-2 (1-4), IL-4 (5-9), IL-7 (10) (11) (12) , tumor necrosis factor (TNF) (13) (14) (15) (16) (17) , interferon y (IFN-y) (18) (19) (20) , macrophage colony-stimulating factor (M-CSF) (21) , granulocyte-CSF (22) , monocyte chemotactic and activating factor (23, 24) , IL-1 (25) ]. An unexpected number of cytokines has been shown to be able to inhibit tumor growth by activation of host-dependent anti-tumor responses. The mechanisms underlying cytokine-induced tumor rejection are of pivotal interest as a contribution to a rational basis for future immunotherapy and may serve to further enlarge the still limited understanding of cytokine action in vivo. However, the immunological mechanisms by which tumors are rejected after cytokine gene transfer are influenced not only by the cytokine but also by the tumor model. Unless analyzed in the same model, differences in the mechanism of tumor rejection cannot conclusively be attributed to the cytokines. Parameters such as the mouse strain, the level of cytokine expression, or the tumor cell line influence the mode of rejection. For example, tumor cells may differ in the susceptibility for host effector mechanisms because of different (i) surface molecule expression [e.g., major histocompatibility complex (MHC), adhesion molecules], (ii) soluble mediators other than the transfected cytokine gene, (iii) growth kinetics, and (iv) immunogenicity. In an effort to more directly compare the mechanisms of tumor rejection induced by different cytokines, we have analyzed five cytokines in parallel in the same tumor cell line with respect to the cellular requirements for tumor rejection.
MATERIALS AND METHODS
Animals. Six-week-old female BALB/c mice or BALB/c nu/nu mice, CB17 severe combined immunodeficient (SCID) or SCID/beige mice were obtained from the Zentralinstitut fur Versuchstierzucht (Hannover, F.R.G.) or from the Gesellschaft fur Strahlenschutz, Munich. NIH III mice (carrying nude, XID, and beige mutations) were obtained from Charles River Breeding Laboratories.
Tumor Cell Line and Genetically Modified Variants. J558L plasmacytoma cells were cultured as published (21) . They neither produce IL-2, IL-4, IL-7, TNF, or IFN-y as determined by the assays described below nor IL-1, IL-3, IL-5, IL-6, M-CSF, or lymphotoxin (not shown). None of the cytokine-producing variants differs from parental cells in cytokine production except for the transfected cytokine. J558L cells express MHC class I and cellular adhesion molecule ICAM I but no detectable MHC class II molecules as determined by fluorescence staining with monoclonal antibodies (mAbs) M142, M5-114, and YN1-1.7 (ATCC) (not shown). None of the transfected variants markedly differs from J558L cells with respect to MHC or ICAM expression. The generation of J558-IL-4 (6), J558-TNF (referred to as JB62 in ref. 17) , and J558-IL-7 cells (10) has been described. J558-IL-4, which was established by retroviral infection, was confirmed to be helper virus free by reverse transcription assay after prolonged culture (not shown). For establishing cell lines J558-IL-2 and J558-IFN, the respective mouse cDNAs were isolated by PCR using reverse transcribed total RNA of ConA-activated spleen T-cell blasts according to published protocols (10, 21) (primers for IL-2: 5'-TGGGATCCTGCAGGCATGTACAGCATGC-3' and 5'-GTGGATCCGGTACATAGTTATTGAGGGCTTG-3'; primers for IFN-y. 5'-CCGAGCGGATTCACCATGAACG-CTACACACTGCATCTTGGC-3' and 5'-CGGCCGGATC-CCGAATCAGCAAGCGACTCCTTTTCCGCTTCCT-GAG-3'). DNA fragments were cloned into the Bgl II site of expression vector pLTR (10) , resulting in plasmids pLTR-IL-2 and pLTR-IFN, which were used to transfect J558L cells along with plasmid pWLneo as described (10) . Transfected cells were selected in G418-containing medium (1 Abbreviations: M-CSF, macrophage colony-stimulating factor; IL, interleukin; NK, natural killer; mAb, monoclonal antibody; TNF, tumor necrosis factor; IFN-y, interferon y; SCID, severe combined immunodeficient; MHC, major histocompatibility complex.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. mg/ml) for 2 weeks, cloned, and tested for activity in the supernatant. The transfectants produced the following amounts of the transfected cytokine: J558-IL-2, 40 units/ml; J558-IL-4, 75 units/ml; J558-IL-7, 50 units/ml; J558-TNF, 17 units/ml; and J558-IFN, 120 ng/ml. Detection of Cytokine Activities. IL-2 and IL-4 were measured by proliferation assays with CTLL-2 (26) or CT.4S (27) cell lines. IL-7 activity was determined by a thymocyte proliferation assay as described (10) . TNF was measured by the L929 cytotoxicity assay as described (14) . Units/milliliter were defined as the reciprocal of supematant dilution (cells were cultured for 48 hr at a concentration of 1 x 106 per ml) yielding half-maximal proliferation/cytotoxicity. IFN-y was measured by an ELISA (Holland Biotechnology, Leiden, The Netherlands) and bioactivity was confirmed by fluorocytometric analysis of induction of MHC class II expression on WEHI 3 cells as described (21) . Specificity was confirmed by addition of blocking mAbs for each cytokine to the bioassays (20 ,g/ml): anti-IL-2 S4B6 (28), anti-IL-4 llBl1 (29), anti-IL-7 mAb (1689-01; Genzyme, Cambridge, MA), anti-IFN-y XMG6 (30) , and rabbit anti-mouse TNF serum (IP400; Genzyme).
Analysis of Tumor Growth. Tumor growth was analyzed as described (10, 14, 21 Immunohistochemistry. Immunohistochemical analysis was done as described (10) SCID/beige (T-, B-, and NK-cell deficient), and NIH III mice (T, B, and NK deficient). In contrast to BALB/c mice, which with few exceptions completely rejected all cytokineproducing J558L variants, almost all nude mice or SCID mice that were injected in parallel eventually developed a tumor (Table 1) . However, marked differences existed in the kinetics of tumor growth comparing cytokine producers and parental cells in T-cell-deficient mice: J558-IL-2, -IL-4, -TNF, and -IFN cells gave rise to tumors with a delay of about 3 weeks compared to parental or J558-IL-7 tumors, indicating these cytokines were able to evoke T-cellindependent mechanisms capable of suppressing tumor growth in the early phase after tumor cell injection. Tumor growth in SCID/beige and NIH III mice was largely indistinguishable from that in nude mice (Table 1) , giving no further clue about these T-cell-independent mechanisms. To investigate the reason for the late outgrowth of tumors, a representative number ofJ558-IL2, -IL4, -TNF, and -IFN-y tumors from nude mice, all ofwhich had been injected at least 30 days previously, were isolated (as described in ref. 21 ) and assayed for cytokine activity. All J558-IL-2 (9/9 tumors), -IL-4 (9/9), or -TNF (8/8) cells had ceased or drastically decreased their cytokine production. However, when tumor suppression in the early phase was blocked by neutralizing antibodies against the cytokine (IL-4) (2/2) or anti-asialo-GM-1 antiserum (IL-2) (2/2), the tumor cells that were reisolated proved to have an unchanged cytokine production. The cytokine secretion of J558-IFN cells was not diminished in 10/12 tumors after in vivo growth in nude mice, although the in vivo growth kinetics were very similar to those of J558-IL-2, -IL-4, and -TNF cells. Reinjection of cells isolated from J558-IFN tumors revealed that they grew as expected from their cytokine production: the nonproducers grew like J558L tumors; the IFN-y producers were initially suppressed in nude and rejected in BALB/c mice (not shown).
Tumor Growth of Cytokine-Producing J558L Cells in Asialo-GM-1+ Cell-Depleted Nude Mice. Spleen cells derived from SCID/beige or NIH III mice were not completely deficient of NK cell activity (data not shown). Thus we further studied the role of NK cells in the tumor suppression of J558-IL-2, -IL-4, -TNF, and -IFN cells in asialo-GM-1+ cell-depleted nude mice. Growth of J558-TNF or J558-IL-4 tumors was either not (IL-4) or only slightly (TNF) accelerated by the anti-asialo-GM-1 serum (not shown). The marginal effect on J558-TNF tumor growth seems negligible considering that the antiserum also accelerates the growth of parental J558L cells (Fig. 1) . However, the asialo-GM-1 antiserum clearly interfered with the anti-tumor activities of IL-2 and IFN-y and restored early tumor growth (Fig. 1) . It should be noted, however, that these tumors still showed a growth retardation in comparison to parental cells, suggest- ing that asialo-GM-1+ cells contribute to IL-2-and IFN-yinduced tumor suppression, but that further non-T-cell effector mechanisms are likely to be involved.
Tumor Growth of Cytokine-Producing J558L Cells in Mice Depleted of CD4+ or CD8+ T Cells. Since complete tumor eradication did not occur in T-cell-deficient animals, the role of T-cell subpopulations was further analyzed by mAbs selectively eliminating either CD4+ or CD8+ T cells for >7 weeks. As shown in Fig. 2 developed and progressively grew in most cases from all five groups. Tumor growth in CD8+ cell-depleted mice closely resembled that in nude mice except for J558-IL-7 tumors, where tumor growth in nude mice was unimpaired.
Immunohistological Analysis of Cytokine-Producing Tumors. Immunohistological analysis of tissue obtained from the site of tumor cell injection between days 3 and 9 (in some cases, 13) enabled us to directly compare the consequences of cytokine production on the infiltrate (Table 2) . Only J558-IL-2, -IL-7, and -TNF tumors were infiltrated by T cells already at early time points. J558-IL-2 tumors were homogenously infiltrated by CD8+ T cells, whereas CD4+ cells were scarcely detectable. J558-IL-7 tumors and, even more rapidly, J558-TNF tumors were densely infiltrated by CD4+ and CD8+ T cells. In some, but not all, J558-IFN tumors a subtle and nonhomogenous infiltration by CD8+ T cells was observed. In J558-IL-4 tumors T cells were absent in the first week but could be detected (scattered) at later time points. The predominant cells found in the infiltrate of all cytokine producers were most likely macrophages, identified by their morphology and positive staining with anti-CR3 (31), -Mac3 (32), and F4/80 (33) mAbs. Whereas in J558-IL-2 and J558-TNF tumors CR3+ cells appeared to be more prominent within the tumor, IL-4 and IL-7 also induced a very pronounced rim around the tumor (not shown). J558-IFN tumors were least infiltrated by CR3+ cells. Eosinophils identified by mAb Nimp-R6 (34) and their characteristic ring-like nucleus were observed to considerably infiltrate J558-IL4 and J558-IL-7 tumors. Notably, we also observed a situation in which cytokine production by J558L cells did not induce any detectable tumor infiltrate: in progressively growing J558-IL-6 tumors (14) the tumor infiltrate did not differ from parental tumors (unpublished observation).
DISCUSSION
The most striking similarity in the tumor rejection induced by all five cytokines was the requirement of CD8+ T cells for complete tumor eradication. However, CD8+ T cells were not necessary for initial tumor suppression, because tumors started to progressively grow only after a latency period in CD8+ T-cell-depleted mice. Similarly, tumors producing IL-2, IL-4, IFN-y, and TNF were initially suppressed in their growth in T-cell-deficient mouse strains. IL-7 differs from the other cytokines inasmuch as CD4+ T cells were needed for the activation of the non-T-effector arm (10) latency period in T-cell-deficient or CD8+ T-cell-depleted animals, it is equally possible that non-T-effector mechanisms keep tumor cells from rapidly expanding, which may give CD8+ T cells the chance to mediate complete tumor cell eradication even without being a direct target for the cytokine produced by the tumor cells. In the case of tumor rejection induced by IL-2, IL-4, TNF, and IFN-'y, CD8+ T cells can serve their function also in long-term CD4+ T-cell-depleted animals (Fig. 2) , indicating that CD4+ helper cell activity either is not needed or can be compensated for by the cytokine production of the tumor cells. The discontinuation of tumor suppression of J558-IL-2, -IL-4, and -TNF in the absence of T cells was always associated with loss of cytokine production. Loss of cytokine production during in vivo growth has already been observed by others (4, 5, 12, 20) and is probably due to preferential killing of cytokine-producing tumor cells and selection of non-cytokine-producing variants. Our results indicate that CD8+ T cells are of pivotal importance for prevention of the outgrowth of non-cytokineproducing variants. This system, however, is not infallible since a few mice developed late tumors also in the presence of T cells and, conversely, some mice completely rejected the tumors in the absence of T cells. The growth of J558-IFN tumors in nude mice illustrates that tumor suppression in the absence of T cells can be transient, although most tumors retain the capability to produce undiminished amounts of IFN-y [similarly for J558-IL-7 tumors in CD8+ T-celldepleted mice (preliminary data)]. In any case, tumor suppression in the absence of CD8+ T cells seemed to be dependent on the continuous presence of the cytokine even if this is not always sufficient for long-term suppression.
The histology of T cells in regressing tumors in the early phase after tumor cell injection allowed no clear prediction of their role in the rejection process. CD8+ T cells were abundantly present early in J558-IL-2, -IL-7, and -TNF tumors, although they were not needed for tumor suppression during this period. Conversely, the role for CD8+ T cells in longterm eradication did not require their early presence since they were only scarcely observed early in the infiltrate of J558-IL-4 or -IFN tumors. CD4+ T cells were found to infiltrate J558-IL-7 and -TNF tumors but for J558-TNF, in contrast to J558-IL-7, their depletion had no effect.
Analysis of T-cell-independent effectors mediating tumor suppression suggests that these mechanisms are at least in part heterogenous. Treatment with an antiserum to asialo-GM-1 could partially restore J558-IL-2 and -IFN, but not J558-IL-4 and -TNF, tumor growth in nude mice. There is an apparent contradiction between the effect of the asialo-GM-1 antiserum (Fig. 1 ) and the lack ofany influence ofthe "beige" mutation (Table 1) , but NK cells are not totally absent in crosses such as SCID/beige or NIH III mice and, moreover, cytokines have been shown to be able to amplify "NK" activity in these strains (35) . The interpretation that indeed NK cell activity was affected by the anti-asialo-GM-1 serum is supported by the finding that an effect very similar to that of anti-asialo-GM-1 was observed with the mAb 30-H12 (not shown) directed against Thy-1.2, which is present on 90% of the NK cells in nude mice (36) . A recent review proposed a crucial role for granulocytes in the tumor inhibition and induction of T-cell responses by several cytokines (37) . However, a final assessment of their role was hampered by the lack of reagents for their specific depletion or inactivation. Using an antibody against granulocytes, at least the eosinophils observed in IL-4-producing tumors have been shown to be important for the tumor-suppressive effect (8) . We could detect eosinophils not only in J558-IL-4 but also in J558-IL-7 tumors; their presence in J558-IL-7 tumors is like the presence of macrophages dependent on CD4+ T cells (data not shown). The macrophages histologically demonstrated in all cytokine-producing tumors under study are further potential effector cells. For TNF, previous experiments showed that tumor suppression depended on CR3+ cells, most probably macrophages, even though the blocking mAb was not completely specific (14) . It (13, 15, 17) . On the other hand, considering the dense infiltration of J558-TNF tumors with CD4+ and CD8+ T cells, it is understandable that both cell populations were necessary for the rejection of another tumor cell line (16) , reasoning that it was less sensitive to T-cell-independent mechanisms. A difference in the susceptibility for host effector mechanisms of the cell line may also be responsible for the different mode of rejection reported for an IL-7-transduced murine glioma that was dependent on CD8+ but not CD4+ T cells (12) , especially since we could observe both T-cell subpopulations in the tumor infiltrate of J558-IL-7 (10) and have demonstrated that CD8+ T cells are also needed in the late phase of tumor rejection. McBride et al. (11) reported a cellular infiltrate in a fibrosarcoma after IL-7 gene transfer, which is very similar to that observed by us in J558-IL-7 tumors. In three reports that have described tumor-suppressive effects of IFN-y after gene transfer, the tumors were reported to grow in nude mice but not in syngeneic mice, firmly establishing a role for T cells in tumor suppression (18) (19) (20) . However, the relative contributions of T-or non-T-effectors appear to be different depending on the cell lines, since we observed IFN-y to be operative in nude mice due to NK cells. Our results and those reported in the literature are compatible with the hypothesis that tumor rejection induced by all five cytokines requires CD8+ T cells and further effector Proc. Natl. Acad. Sci. USA 90 (1993) cells, which vary depending on the cytokine. The relative contributions of the different effectors appear to be influenced by the particular tumor model.
